Cybin Inc.
https://www.cybin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cybin Inc.
Lykos’s Knockback Could Be An Opportunity For Rivals
The group intends to appeal the US FDA’s rejection of its MDMA-based PTSD therapy, midomafetamine, but other psychedelics could advance in the meantime.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Cybin High On Psychedelic-Based CYB003 For MDD
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Cybin IRL Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice